4basebio Plc - Grant received from the Bill and Melinda Gates Foundation

  1 August 2023

4basebio PLC

("4basebio", the "Company" or the "Group")

4basebio receives grant to advance its synthetic DNA platform and Hermes™ nanoparticle platform for the development of
thermostable nucleic acid vaccines

• Funding from the Bill & Melinda Gates Foundation will build on preclinical data demonstrating superior immune responses achieved with 4basebio's synthetic DNA products as well as improved stability offered by its Hermes™ platform.

Cambridge, UK, 1 August 2023 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, today announces it has received a grant from the Bill & Melinda Gates Foundation (the "Foundation") to advance the development program of thermostable nucleic acid based vaccines.

The development program aims to build on preclinical data demonstrating the improved stability offered by the Hermes™ platform, the superior immune responses achieved with 4basebio's synthetic DNA products and high-quality mRNA produced from 4basebio opDNA™ products.

The successful demonstration of the Hermes™ platform and 4basebio synthetic nucleic acid payloads in infectious disease vaccines has the potential to enhance the global availability of such innovative medicines.

Heikki Lanckriet, CEO and CSO of 4basebio, commented: "The Foundation's grant recognises the potential of our Hermes™ and synthetic DNA platforms. The enhanced stability offered by our vectors as well as the rapid turnaround time offered through our synthetic DNA has the potential to enable a faster response to pandemic needs and create highly performant and affordable vaccine products in support of the global fight against infectious diseases."

For further enquiries, please contact:

4basebio PLC                                                                       +44 (0)12 2396 7943

Heikki Lanckriet

Nominated Adviser                                                            +44 (0)20 7213 0880

Cairn Financial Advisers LLP

Jo Tuner / Sandy Jamieson

Broker                                                                                  +44 (0)20 7220 0500

finnCap Ltd

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Lionsgate Communications (Media Enquiries)                 +44 (0)77 91892509
Jonathan Charles

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed on accelerating the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The Company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.

Forward-looking statements

This announcement may contain certain statements about the future outlook for the 4basebio.  Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.